These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 9826984)

  • 1. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
    Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Medical treatment of spasticity].
    Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traditional pharmacological treatments for spasticity. Part I: Local treatments.
    Gracies JM; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S61-91. PubMed ID: 9826983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Orally administered drugs in the treatment of spasticity].
    Campistol J
    Rev Neurol; 2003 Jul 1-15; 37(1):70-4. PubMed ID: 12861514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of botulinum toxin in the treatment of spasticity.
    Simpson DM
    Muscle Nerve Suppl; 1997; 6():S169-75. PubMed ID: 9826988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders.
    Wagstaff AJ; Bryson HM
    Drugs; 1997 Mar; 53(3):435-52. PubMed ID: 9074844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
    Kofler M; Quirbach E; Schauer R; Singer M; Saltuari L
    Neurorehabil Neural Repair; 2009 Jan; 23(1):26-31. PubMed ID: 18796543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of spasticity with the intrathecal administration of baclofen].
    Lazorthes Y; Sallerin B; Verdié JC; Casaux J; Caraoué F; Sol JC
    Neurochirurgie; 1998 Sep; 44(3):201-8. PubMed ID: 9827437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional outcome of intrathecal baclofen administration for severe spasticity.
    Boviatsis EJ; Kouyialis AT; Korfias S; Sakas DE
    Clin Neurol Neurosurg; 2005 Jun; 107(4):289-95. PubMed ID: 15885386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group.
    Smith C; Birnbaum G; Carter JL; Greenstein J; Lublin FD
    Neurology; 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3. PubMed ID: 7970009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of intrathecal baclofen in the treatment of spasticity in stroke].
    Lamotte D; Cantalloube S
    Ann Readapt Med Phys; 2007 Apr; 50(3):165-9. PubMed ID: 17145092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Spasticity treatment with spinal morphine or midazolam. In vitro experiments, animal studies and clinical studies on compatibility and effectiveness].
    Müller H; Gerlach H; Boldt J; Börner U; Hild P; Oehler KU; Zierski J; Hempelmann G
    Anaesthesist; 1986 May; 35(5):306-16. PubMed ID: 2943190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury.
    Mathias CJ; Luckitt J; Desai P; Baker H; el Masri W; Frankel HL
    J Rehabil Res Dev; 1989; 26(4):9-16. PubMed ID: 2600869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological interventions for spasticity following spinal cord injury.
    Taricco M; Adone R; Pagliacci C; Telaro E
    Cochrane Database Syst Rev; 2000; 2000(2):CD001131. PubMed ID: 10796750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.